Search

Poor adherence to asthma and chronic obstructive pulmonary disease (COPD) maintenance therapies impairs health outcomes. Proven and cost-effective programs to promote adherence and persistence are not yet in widespread, regular use. Implementation costs are a potential barrier to uptake of such programs.

This study focuses on the comparison between two similar hydraulic excavators: (i) a traditional excavator and (ii) a Global Positioning System (GPS) instrumented excavator. Both the machines were monitored for the work they performed. This included the moving of large masses of earth as well as finishing tasks of profile refinement (with a constrained accuracy of ± 10cm). The comparison included the efficiency of machines and attained accuracy as well as their environmental impact with regards to emissions into the atmosphere. The environmental impact calculations were conducted by means of the ECORCE application, a numerical tool for Life Cycle Assessment of road developed at the French Institute of Science and Technology for Transport, Development and Networks (Ifsttar). The monitoring highlighted the fact that GPS-instrumented excavator fully conformed to the accuracy requirements for earth moving. The use of the GPS technology resulted in 1/3 and 2/3 reductions of fuel consumption and finishing working time, respectively. This also contributed to lower both the potential environmental impacts (i.e. global warming potential, acidification potential, eutrophication index, photochemical ozone and eco-toxicity potential indicated) and the related costs.

Muresan: Ingress-health Nederland BV: Employment. Mamolo:Pfizer: Employment, Equity Ownership. Cappelleri:Pfizer: Employment, Equity Ownership. Mokgokong:Pfizer Inc: Equity Ownership. Palaka:Pfizer Inc: Employment, Equity Ownership. Hills:Daiichi Sankyo: Consultancy, Honoraria. Latimer:Astra Zeneca: Consultancy; Merck: Consultancy; Pfizer: Consultancy; BMS: Consultancy; Janssen: Consultancy; Bluebirdbio: Consultancy. Heeg:Ingress-health Nederland BV: Employment, Equity Ownership, Research Funding.

Muresan: Ingress-health Nederland BV: Employment. Mamolo:Pfizer: Employment, Equity Ownership. Cappelleri:Pfizer: Employment, Equity Ownership. Crescenzo:Pfizer: Employment. Leip:Pfizer: Employment, Equity Ownership. Viqueira:Pfizer: Employment, Equity Ownership. Heeg:Ingress-health Nederland BV: Employment, Equity Ownership, Research Funding.

Introduction:Gemtuzumab ozogamicin (GO; MylotargTM) was approved by the US Food and Drug Administration in 2017 and the European Medicines Agency in 2018 in combination with standard of care (SOC) chemotherapy (daunorubicin/cytarabine) for the treatment of de novo acute myeloid leukemia (AML). Although initial remission rates for de novo AML are high, overall survival (OS) is low; however, a proportion of patients experience long-term remission (>5 years) and can be considered cured. Statistically cured populations can be estimated by fitting mixture cure models (MCMs) to survival data, a method that takes into account background survival rates. The objective of this research was to assess and compare the statistical cure rates with GO plus SOC vs SOC alone among adult patients with de novo AML.

Introduction

Muresan: Ingress-health Nederland BV: Employment. Mamolo:Pfizer Inc: Employment, Equity Ownership. Cappelleri:Pfizer Inc: Employment, Equity Ownership. Shapiro:Pfizer Inc: Employment, Equity Ownership. Crescenzo:Pfizer Inc: Employment. Su:Pfizer: Employment, Equity Ownership; Bristol Myers Squibb: Equity Ownership. Heeg:Ingress-health Nederland BV: Employment, Equity Ownership, Research Funding.

Background: In clinical trials of second line and later line therapies for chronic myeloid leukemia (CML), to date only single arm trials have been conducted for the available treatments (i.e. Bosutinib, Dasatinib, Nilotinib and Ponatinib). These trials included heterogeneous patient populations in terms of line of treatment, stage of disease and other patient- and disease baseline characteristics that may impact the outcomes of the treatment. This hampers any direct or indirect comparisons of these second line CML treatments in terms of efficacy measures such as progression-free survival (PFS) and overall survival (OS). In this situation (i.e. lack of common comparator), matching-adjusted indirect treatment comparisons (MAICs) can be applied.